BET

"Beyond the Red Carpet" presents an unprecedented range of globally renowned awards as fine art, cultural treasures and corporate masterpieces

Retrieved on: 
Monday, December 4, 2023
BMW, NBA, NBC, Organization, Human voice, MTV, Mint Museum, Music, Red, WNBA, Dance, FAILE (artist collaboration), Clio Awards, YouTube Creator Awards, ABC, National Association, Country music, NFL, Council, MLB, IHeartRadio, Fashion, Dancing with the Stars, NAACP, Exhibition, Television, Society Awards, NHL, BET, Science, Red carpet, Academy of Country Music, The Recording Academy, Interior design, Accenture

The exhibition spotlights the artistic and artisanal aspects of luxury awards.

Key Points: 
  • The exhibition spotlights the artistic and artisanal aspects of luxury awards.
  • Many of the designs include collaboration with notable artists such as Jeff Koons and Kehinde Wiley.
  • Press Contact: Interview opportunities with David Moritz, the CEO and Founder of Society Awards, can be requested by emailing [email protected] .
  • For more information about the Society Awards + Mint Museum "Beyond the Red Carpet" exhibition, and to explore the luxurious world of awards, please visit societyawards.com/mintmuseum .

One United Properties signs a memorandum of understanding with Ennismore for opening Mondrian Bucharest, a highly exclusive lifestyle hotel in downtown Bucharest, close to the Romanian Athénée

Retrieved on: 
Tuesday, November 14, 2023
Acquisition, Mondrian Hotel, Ford, Accor, Creativity, Investment, Tourism, Gold, FTSE, Heart, Ennismore, Partnership, Bucharest Stock Exchange, Morgans Hotel Group, Project One (gallery), BVB, BET, MSCI, Carl Pohlad, Piet Mondrian, Hong Kong

The partnership will focus on delivering Mondrian Bucharest, a unique lifestyle hotel in downtown Bucharest.

Key Points: 
  • The partnership will focus on delivering Mondrian Bucharest, a unique lifestyle hotel in downtown Bucharest.
  • Mondrian Hotel opened first in 1985 in Los Angeles as the Le Mondrian by the L'Ermitage Hotel Group, and was later purchased by Ian Schrager and his Morgans Hotel Group in 1996 and renamed Mondrian Hotel Los Angeles.
  • Mondrian Bucharest will be located at 8-10 Georges Clemenceau Street, near the Romanian Athénée, where One United Properties has previously bought an unfinished building with the intention to transform it into a hotel.
  • Mondrian is not just a hotel; it's a lifestyle brand, promising a new era of sophisticated experiences and elevated living.

EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million

Retrieved on: 
Thursday, December 14, 2023
XETRA, Financial services, Ruxolitinib, Relevance (Person of Interest), Frankfurt Stock Exchange, Regulation, Person, FSE, Wells Fargo, AMERICA, Qualification, Gross metropolitan product, Prospectus, Investment, EUR, Failure, MorphoSys, UBS, SEC Rule 144A, European Parliament, European Economic Area, Finance, BET, Council, Truist, Jefferies, Acquisition, EEA, Security (finance), Pharmaceutical industry, Order

The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.

Key Points: 
  • The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.
  • “MorphoSys’ oncology pipeline offers promising value-creating opportunities, with pelabresib, our investigational BET inhibitor, at the forefront,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
  • “With pelabresib, we have the potential to shift the treatment paradigm in myelofibrosis, a field in dire need of innovation.
  • The placement price represents a discount of 2.8% compared to the 5-day volume-weighted average price (XETRA) of the Company’s shares.

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Annual general meeting, Food, Fast Track, Ruxolitinib, Conference call, BET, FSE, EZH2, CET, EZH1, JAK, Society, FDA, ASH, Abstract, PST, Patient, Conference, Webcast, ARID1A, Pharmaceutical industry, Cryptocurrency, Video game, Tafasitamab, MorphoSys

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.

Key Points: 
  • “With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.
  • Total revenues for the third quarter 2023 were € 63.8 million compared to € 95.8 million for the same period in 2022.

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Retrieved on: 
Tuesday, November 7, 2023
Psoriasis, BET, Therapy, Patient, Rheumatoid arthritis, Pharmaceutical industry

BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced it will host a virtual R&D Day event on Thursday, November 9, 2023 at 1:30 p.m. ET. To register, click here.

Key Points: 
  • Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans
    BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced it will host a virtual R&D Day event on Thursday, November 9, 2023 at 1:30 p.m.
  • The event will feature a presentation from Dr. Amit Pandya, former President of the Global Vitiligo Foundation.
  • VYNE management will discuss the final results from the Phase 1b trial for VYN201 in patients with nonsegmental vitiligo.
  • In addition, VYNE management will review the preclinical data for its oral BD2-selective BET inhibitor, VYN202, in psoriasis and rheumatoid arthritis and discuss its development plans for both programs.

EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Standard of care, Primary myelofibrosis, Progression-free survival, 65th United States Congress, Ruxolitinib, Research, JAK, Society, Abstract (summary), ASH, Clinical trial, Abstract, FSE, Tafasitamab, BET, Exposition, Patient, TSS, Joint Planning and Development Office, Pharmaceutical industry, Book, MorphoSys

The conference is being held in San Diego, California, from December 9 to 12, 2023.

Key Points: 
  • The conference is being held in San Diego, California, from December 9 to 12, 2023.
  • “We will be sharing topline results from our pivotal MANIFEST-2 study in the coming weeks and look forward to presenting detailed findings at ASH 2023 shortly thereafter.
  • A total of 431 patients were randomized in the study, making it one of the largest myelofibrosis studies conducted to date.
  • One additional abstract on pelabresib and six abstracts on tafasitamab, marketed in the U.S. as Monjuvi® and outside the U.S. by Incyte as Minjuvi®, were accepted for presentation and publication at ASH 2023.

VYNE Therapeutics Announces Private Placement of $88 Million

Retrieved on: 
Monday, October 30, 2023
Sale, Security (finance), Vitiligo, Prospectus, BET, PIPE, Therapy, Patient, Citadel

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of $88 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of $88 million, before deducting placement agent fees and offering expenses.
  • “We are proud to partner with leading fundamental healthcare investors in this transformative financing of our company to advance our InhiBET™ platform,” said David Domzalski, President and Chief Executive Officer of VYNE.
  • “This is an exciting time at VYNE as we announce positive clinical data from our Phase 1b trial evaluating VYN201 in patients with nonsegmental vitiligo.
  • LifeSci Capital LLC is acting as the exclusive placement agent for the PIPE.

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Retrieved on: 
Monday, October 30, 2023
Inflammatory arthritis, Psoriasis, IND, Vitiligo, Mouse, Pathology, Bone erosion, IL-6, Rheumatoid arthritis, Phenotype, R, Granulation tissue, Disease, Animal, BET, Therapy, TYK2, Pharmaceutical industry, Medical device, Copper, Palladium

“These compelling preclinical data in skin inflammation and joint disease models highlight VYN202’s potential for therapeutic utility in both psoriasis and rheumatoid arthritis.

Key Points: 
  • “These compelling preclinical data in skin inflammation and joint disease models highlight VYN202’s potential for therapeutic utility in both psoriasis and rheumatoid arthritis.
  • Treatment was then administered intraperitoneally with either VYN202, deucravacitinib (an allosteric TYK2 inhibitor), or placebo.
  • Each treatment group orally received either placebo, GSK620 (an early generation BD2-selective BET inhibitor) at 10 mg/kg, or VYN202 at three different dose strengths (1, 3, or 10 mg/kg).
  • If successful, VYNE anticipates commencing Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024.

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Retrieved on: 
Monday, October 30, 2023
Vitiligo, Pigment, Boston Medical Group, Pharmacokinetics, Skin, Tolerability, Autoimmune disease, BET, Safety, Initiate, Therapy, Depigmentation, Patient, Pharmaceutical industry, Vaccine

The Phase 1b trial is a 16-week open-label trial assessing the safety, tolerability and pharmacokinetics of once-daily topical VYN201 in 29 patients across three dose cohorts (0.5%, 1.0% and 2.0% strengths).

Key Points: 
  • The Phase 1b trial is a 16-week open-label trial assessing the safety, tolerability and pharmacokinetics of once-daily topical VYN201 in 29 patients across three dose cohorts (0.5%, 1.0% and 2.0% strengths).
  • “We are encouraged by these data from our Phase 1b trial that demonstrate proof-of-concept in nonsegmental vitiligo, which we believe is the first clinical evidence of a BET inhibitor’s effect in autoimmune disease.
  • VYNE management will review the final results from the Phase 1b trial for VYN201.
  • The VYNE team will also discuss the Company’s development plans for VYN201 and its oral BET inhibitor VYN202.

2024 PEGASUS WORLD CUP PRESENTED BY BACCARAT RETURNS TO SOUTH FLORIDA ON JANUARY 27

Retrieved on: 
Monday, November 6, 2023
Komodo, Venus, Jazz, GIII, Arrogate, Sale, Attention, 1/ST, Usher, Grammy Awards, Horse, Gulfstream Park, History, LIV, DJ, Angel, Biting, Pegasus World Cup Invitational Stakes, Life, City, Knicks Go, DJ Cassidy, Baccarat, Pegasus, Jazz Age, Music, Maison, Gavin de Becker and Associates, BET, Pegasus World Cup Turf Invitational, Table, American Horse, Calendar, OneRepublic, VIP, Nightclub, Hotel, Amusement park

HALLANDALE BEACH, Fla., Nov. 6, 2023 /PRNewswire/ -- The hottest party on the international Thoroughbred racing calendar returns to Gulfstream Park on Saturday, January 27, as 1/ST announces the 2024 Pegasus World Cup Presented by Baccarat. Known for attracting world-class Thoroughbred racehorses, A-list celebrity attendees, tastemakers, influencers, and avid racing fans, 1/ST has once again partnered with Palm Tree Crew and David Grutman's Groot Hospitality to curate a unique Miami experience including an unforgettable headline performance by Grammy award-winning producer, DJ, and songwriter Calvin Harris.

Key Points: 
  • Setting the stage for one of the most thrilling dates on the racing calendar, the 2024 Pegasus World Cup Presented by Baccarat will feature the $3 million Pegasus World Cup Championship Invitational (GI), the $1 million Pegasus World Cup Championship Turf Invitational (GI), and the $500,000 Pegasus World Cup Filly & Mare Turf Invitational (GIII).
  • Baccarat will also return as the Official Trophy Purveyor to create the 2024 Pegasus World Cup championship trophies.
  • The limited-production Pegase Horse in Black, valued at $47,000, will be presented to the Pegasus World Cup Invitational winner, and the Pegase Horse in Clear, valued at $39,000, will be presented to the Pegasus World Cup Turf Invitational winner.
  • The Pegasus World Cup Championship Invitational Series has welcomed legendary Thoroughbred racehorses, including Arrogate (Longines World's Best Racehorse 2016 and 2017 Pegasus World Cup Invitational winner), California Chrome (two-time American Horse of the Year 2014 & 2016 and 2017 Pegasus World Cup Invitational runner-up), Gun Runner (American Horse of the Year 2017 and 2018 Pegasus World Cup Invitational winner), City of Light (2019 Pegasus World Cup Invitational winner), Mucho Gusto (2020 Pegasus World Cup Championship Invitational winner), Knicks Go (2021 Pegasus World Cup Invitational winner), Life is Good (2022 Pegasus World Cup Invitational Winner), and Art Collector (2023 Pegasus World Cup Invitational Winner).